Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DEHP/PVC

This article was originally published in The Gray Sheet

Executive Summary

FDA expects to issue a guidance on labeling for devices containing di(2-ethylhexyl)phthalate (DEHP) "in the very near future," according to an April 5 letter from the agency to Health Care Without Harm denying the group's Oct. 5, 2001 petition for reconsideration. In September 2001, the agency denied HCWH's initial citizen petition requesting that all polyvinyl chloride medical devices be required to bear warning labels and that FDA encourage the development of alternatives to PVC (1"The Gray Sheet" Sept. 10, 2001, p. 18). In the April letter, FDA maintains that HCWH failed to satisfy the criteria required for the agency to grant a petition for reconsideration...

You may also be interested in...



DEHP Study Prompts FDA To Consider Safety/Availability Of PVC Alternatives

FDA will examine the safety and availability of alternatives to devices containing the plasticizer di-2-ethylhexyl-phthalate (DEHP) before considering a risk management strategy.

Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer

Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.

Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date

ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel